Found: 7
Select item for more details and to access through your institution.
p38 MAPK inhibition reduces diabetes-induced impairment of wound healing.
- Published in:
- Diabetes, Metabolic Syndrome & Obesity: Targets & Therapy, 2009, v. 2, p. 91
- By:
- Publication type:
- Article
Inhibition of ATP synthase reverse activity restores energy homeostasis in mitochondrial pathologies.
- Published in:
- EMBO Journal, 2023, v. 42, n. 10, p. 1, doi. 10.15252/embj.2022111699
- By:
- Publication type:
- Article
(-)-Epicatechin induces mitochondrial biogenesis and markers of muscle regeneration in adults with Becker muscular dystrophy.
- Published in:
- 2021
- By:
- Publication type:
- journal article
Pharmacological Properties of SD-282 – An α-Isoform Selective Inhibitor for p38 MAP Kinase.
- Published in:
- Pharmacology, 2007, v. 81, n. 3, p. 204, doi. 10.1159/000112865
- By:
- Publication type:
- Article
SPR965, a Dual PI3K/mTOR Inhibitor, as a Targeted Therapy in Ovarian Cancer.
- Published in:
- Frontiers in Oncology, 2021, v. 11, p. N.PAG, doi. 10.3389/fonc.2020.624498
- By:
- Publication type:
- Article
Progressive Transforming Growth Factor β1-induced Lung Fibrosis Is Blocked by an Orally Active ALK5 Kinase Inhibitor.
- Published in:
- American Journal of Respiratory & Critical Care Medicine, 2005, v. 171, n. 8, p. 889, doi. 10.1164/rccm.200405-612OC
- By:
- Publication type:
- Article
Safety and efficacy of (+)‐epicatechin in subjects with Friedreich's ataxia: A phase II, open‐label, prospective study.
- Published in:
- Journal of Inherited Metabolic Disease, 2021, v. 44, n. 2, p. 502, doi. 10.1002/jimd.12285
- By:
- Publication type:
- Article